REVVITY, INC.
RVTYAPI behind this page
RVTY Q1 2026 request
Playground key active
/api/financials?ticker=RVTY&year=2026&quarter=1
Pick an endpoint and run the request.Income Statement
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Revenue | 711,118 | 664,762 | +7.0% |
Show Product Lines breakouts |
|||
| Product | 581,458 | 562,680 | +3.3% |
| Service | 129,660 | 102,082 | +27.0% |
Show Business Segments breakouts |
|||
| Diagnostics [Member] | 349,273 | 324,367 | +7.7% |
| Diagnostics [Member] · Americas | 130,441 | 120,350 | +8.4% |
| Diagnostics [Member] · Asia | 87,481 | 98,247 | -11.0% |
| Diagnostics [Member] · Europe | 131,351 | 105,770 | +24.2% |
| Diagnostics [Member] · Immunodiagnostics [Member] | 201,831 | 197,562 | +2.2% |
| Diagnostics [Member] · Reportable Segment Revenue [Member] | 349,273 | 324,367 | +7.7% |
| Diagnostics [Member] · Reproductive health [Member] | 147,442 | 126,805 | +16.3% |
| Life Sciences [Member] | 361,845 | 340,395 | +6.3% |
| Life Sciences [Member] · Americas | 185,551 | 184,279 | +0.7% |
| Life Sciences [Member] · Asia | 84,599 | 80,094 | +5.6% |
| Life Sciences [Member] · Europe | 91,695 | 76,022 | +20.6% |
| Life Sciences [Member] · Life Sciences Solutions [Member] | 299,996 | 286,453 | +4.7% |
| Life Sciences [Member] · Reportable Segment Revenue [Member] | 361,845 | 340,395 | +6.3% |
| Life Sciences [Member] · Software [Member] | 61,849 | 53,942 | +14.7% |
Show Geography breakouts |
|||
| Americas | 315,992 | 304,629 | +3.7% |
| Asia | 172,080 | 178,341 | -3.5% |
| Europe | 223,046 | 181,792 | +22.7% |
Show Major goods/service lines [Axis] breakouts |
|||
| Immunodiagnostics [Member] | 201,831 | 197,562 | +2.2% |
| Life Sciences Solutions [Member] | 299,996 | 286,453 | +4.7% |
| Reproductive health [Member] | 147,442 | 126,805 | +16.3% |
| Software [Member] | 61,849 | 53,942 | +14.7% |
Show Segment Reporting [Axis] breakouts |
|||
| Reportable Segment Revenue [Member] | 711,118 | 664,762 | +7.0% |
| Cost of Revenue | 323,463 | 289,216 | +11.8% |
Show Product Lines breakouts |
|||
| Product | 273,320 | 250,155 | +9.3% |
| Service | 50,143 | 39,061 | +28.4% |
| Selling, General & Administrative | 253,882 | 249,719 | +1.7% |
| Research & Development | 57,887 | 53,597 | +8.0% |
| Operating Income | 75,886 | 72,230 | +5.1% |
| Interest And Other Expense Net | 25,894 | 19,848 | +30.5% |
| Income Before Taxes | 49,992 | 52,382 | -4.6% |
| Income Tax Expense (Benefit) | 9,099 | 10,713 | -15.1% |
| Income Loss From Continuing Operations | 40,893 | 41,669 | -1.9% |
| Income Loss From Discontinued Operations Net Of Tax | -175 | 568 | -130.8% |
| Net Income | 40,718 | 42,237 | -3.6% |
Show Equity Components breakouts |
|||
| Retained Earnings | 40,718 | 42,237 | -3.6% |
| Income Loss From Continuing Operations Per Basic Share | 0.37 | 0.35 | +5.7% |
| Income Loss From Discontinued Operations Net Of Tax Per Basic Share | 0 | 0 | — |
| EPS (Basic) | 0.36 | 0.35 | +2.9% |
| Income Loss From Continuing Operations Per Diluted Share | 0.37 | 0.35 | +5.7% |
| Income Loss From Discontinued Operations Net Of Tax Per Diluted Share | 0 | 0 | — |
| EPS (Diluted) | 0.36 | 0.35 | +2.9% |
| Wtd Avg Shares (Basic) | 111,852 | 120,137 | -6.9% |
| Wtd Avg Shares (Diluted) | 111,876 | 120,233 | -7.0% |
| Non-Operating Income (Expense) | 25,894 | 19,848 | +30.5% |
| Interest Expense | 24,718 | 22,964 | +7.6% |
| Interest Income | -6,304 | -10,081 | +37.5% |
| Comprehensive Income | 9,297 | 121,891 | -92.4% |
Balance Sheet
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 860,320 | 1,137,620 | -24.4% |
| Accounts Receivable | 691,380 | 617,418 | +12.0% |
| Inventory | 387,505 | 381,308 | +1.6% |
| Other Assets Current | 189,112 | 181,592 | +4.1% |
| Total Current Assets | 2,128,317 | 2,317,938 | -8.2% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 465,636 | 486,711 | -4.3% |
| Operating Lease Right-of-Use Assets | 163,254 | 173,667 | -6.0% |
| Goodwill | 6,610,750 | 6,511,488 | +1.5% |
Show Business Segments breakouts |
|||
| Diagnostics [Member] | 1,858,705 | 1,936,289 | -4.0% |
| Life Sciences [Member] | 4,752,045 | 4,575,199 | +3.9% |
| Other Non-Current Assets | 322,099 | 299,552 | +7.5% |
| Total Assets | 11,996,590 | 12,360,724 | -2.9% |
| Intangible Assets | 2,306,534 | 2,571,368 | -10.3% |
Show Finite and Indefinite Lived Intangible Assets by Major Class [Axis] breakouts |
|||
| Core Technology [Member] | 695,104 | 798,538 | -13.0% |
| Customer Relationships | 1,557,383 | 1,709,097 | -8.9% |
| Licensing Agreements | 7,336 | 8,911 | -17.7% |
| Patents | 1,013 | 1,450 | -30.1% |
| Trade Names And Trademarks [Member] | 45,698 | 53,372 | -14.4% |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 2,306,534 | 2,571,368 | -10.3% |
| Current Liabilities | |||
| Current Portion of Long-Term Debt | 575,831 | — | — |
Show Fair Value Hierarchy breakouts |
|||
| Fair Value Inputs Level2 · 1.875 Percent Ten Year Senior Unsecured Notes [Member] | 575,831 | — | — |
| Accounts Payable | 169,679 | 178,086 | -4.7% |
| Accrued Liabilities | 493,134 | 469,859 | +5.0% |
| Total Current Liabilities | 1,238,644 | 648,187 | +91.1% |
| Deferred Revenue | 171.7 | — | — |
| Non-Current Liabilities | |||
| Long-Term Debt | 2,632,072 | 3,168,384 | -16.9% |
| Other Non-Current Liabilities | 800,859 | 750,284 | +6.7% |
| Operating Lease Liabilities | 142,276 | 156,739 | -9.2% |
| Total Liabilities | 4,813,851 | 4,723,594 | +1.9% |
| Long-Term Debt (Q) | — | — | — |
Show Fair Value Hierarchy breakouts |
|||
| Fair Value Inputs Level2 | 2,632,072 | 3,168,384 | -16.9% |
| Fair Value Inputs Level2 · 1.900% Senior Unsecured Notes due 2028 [Member] | 498,231 | 497,545 | +0.1% |
| Fair Value Inputs Level2 · 2.250% Senior Unsecured Notes due in 2031 [Member] | 496,580 | 496,001 | +0.1% |
| Fair Value Inputs Level2 · 2.55 Percent Senior Unsecured Notes due in 2031 [Member] | 398,058 | 397,692 | +0.1% |
| Fair Value Inputs Level2 · 3.3 Percent Ten Year Senior Unsecured Notes due in Sept 2029 [Member] | 845,851 | 844,764 | +0.1% |
| Fair Value Inputs Level2 · 3.625 Percent Senior Unsecured Notes due in 2051 [Member] | 396,029 | 395,938 | 0.0% |
| Fair Value Inputs Level2 · Senior Unsecured Notes [Member] | 3,210.6 | 3,171.5 | +1.2% |
Show Debt Instrument breakouts |
|||
| Line of Credit, Maturing January 7, 2030 | 2,677 | 3,320 | -19.4% |
| Stockholders' Equity | |||
| Common Stock | 111,629 | 119,409 | -6.5% |
| Additional Paid In Capital Common Stock | 1,237,444 | 1,954,955 | -36.7% |
| Retained Earnings | 6,087,222 | 5,879,217 | +3.5% |
| Accumulated Other Comprehensive Income | -253,556 | -316,451 | +19.9% |
| Total Stockholders' Equity | 7,182,739 | 7,637,130 | -5.9% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | -253,556 | -316,451 | +19.9% |
| Additional Paid In Capital | 1,237,444 | 1,954,955 | -36.7% |
| Common Stock | 111,629 | 119,409 | -6.5% |
| Retained Earnings | 6,087,222 | 5,879,217 | +3.5% |
| Total Liabilities & Equity | 11,996,590 | 12,360,724 | -2.9% |
Cash Flow Statement
| Metric | YTD Q1 2026 | YTD Q1 2025 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Restructuring And Other Costs | 10,675 | 3,239 | +229.6% |
| Depreciation & Amortization | 105,056 | 97,422 | +7.8% |
| Gain Loss On Sale Of Business | -5,074 | — | — |
| Stock-Based Compensation | 8,715 | 7,731 | +12.7% |
| Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 | -99 | -625 | +84.2% |
| Amortization Of Financing Costs And Discounts | 1,139 | 1,102 | +3.4% |
| Change In Fair Value Of Financial Securities | 4,204 | -3,073 | +236.8% |
| Foreign Currency Transaction Gain Loss Unrealized | 100 | -66 | +251.5% |
| Change in Accounts Receivable | 61,547 | 18,140 | +239.3% |
| Change in Inventory | -12,838 | -5,486 | -134.0% |
| Change in Accounts Payable | -13,744 | 8,854 | -255.2% |
| Increase Decrease In Accrued Liabilities And Other Operating Liabilities | -74,687 | -34,810 | -114.6% |
| Net Cash Provided By Used In Operating Activities Continuing Operations | 125,887 | 134,097 | -6.1% |
| Cash Provided By Used In Operating Activities Discontinued Operations | -10,657 | -5,942 | -79.4% |
| Net Cash from Operations | 115,230 | 128,155 | -10.1% |
| Investing Activities | |||
| Capital Expenditures | -19,775 | -15,982 | -23.7% |
| Purchases Of Investments And Notes Receivables | -1,055 | — | — |
| Proceeds From Investments And Notes Receivables | 677 | — | — |
| Proceeds From Sale Of Property Plant And Equipment | 9,003 | — | — |
| Proceeds From Divestiture Of Businesses | 158 | 229 | -31.0% |
| Payments For Acquisitions And Investments Net Of Cash And Cash Equivalents Acquired | -67,280 | — | — |
| Net Cash Provided By Used In Investing Activities Continuing Operations | -78,272 | -15,753 | -396.9% |
| Net Cash from Investing | -78,272 | -6,378 | -1127.2% |
| Financing Activities | |||
| Proceeds From Stock Options Exercised | 5,441 | 2,632 | +106.7% |
| Share Repurchases | -86,496 | -153,594 | +43.7% |
| Payments Of Dividends Common Stock | -7,840 | -8,433 | +7.0% |
| Net Cash from Financing | -88,895 | -163,664 | +45.7% |
| Supplemental | |||
| Restricted Cash Current | 428 | 1,067 | -59.9% |
| Restricted Cash Noncurrent | 718 | — | — |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | -7,627 | 16,122 | -147.3% |
| Net Change in Cash | -59,564 | -25,765 | -131.2% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 861,466 | 1,138,687 | -24.3% |
Values in thousands USD. Source: SEC EDGAR 10-Q filing.